Natera’s Earnings Call Signals Strong Growth Momentum

Natera Inc. ((NTRA)) has held its Q1 earnings call. Read on for the main highlights of the call.

Natera’s latest earnings call struck an emphatically upbeat tone, with management highlighting broad-based momentum across oncology and women’s health. Revenue, volumes, and pricing all moved higher, margins beat expectations, and guidance was raised despite acknowledged short-term headwinds in collections, coverage, and operational timing that executives framed as transitory rather than structural.

Record Revenue Growth Fueled by Volume and Pricing

Natera reported first-quarter revenue of $697 million, up 39% year over year, driven by a combination of strong test volume and better pricing. Management emphasized that this top-line performance reflects both expanded adoption across product lines and improving economics per test, underscoring the leverage in its business model.

Crossing the 1 Million Unit Quarterly Threshold

The company processed 1 million units in a single quarter for the first time, marking a significant scale milestone. Executives framed this as evidence that Natera can handle rapidly rising demand without sacrificing operational execution, supporting their confidence in sustaining high growth.

Oncology Volumes Surge as Signatera Scales

Oncology remained the primary growth engine, with 249,000 clinical minimal residual disease tests processed in the quarter, a 55% year-over-year increase and about 24,000 higher than the prior quarter. This performance implies an annual run rate above 1 million MRD tests, reinforcing Signatera’s position as a leading oncology platform and expanding its revenue base.

Fetal Focus Supports Women’s Health Momentum

Natera’s women’s health portfolio also showed momentum, led by the Fetal Focus launch, which is already approaching a nearly 200,000 annualized order run rate. Core women’s health added around 63,000 units quarter over quarter, signaling that the company’s legacy franchise continues to grow alongside oncology.

ASPs Rise with Long-Term Upside Remaining

Average selling prices improved across key franchises, with Signatera ASPs reaching roughly $1,250 this quarter. Management reiterated a long-term target of $2,000 per test, which they estimate could translate into about $750 million of incremental revenue at today’s volumes, highlighting a sizable pricing and profitability lever.

Gross Margin Beat and Guidance Reset Higher

Gross margin came in just under 65%, ahead of prior guidance that assumed a 64% midpoint, despite several temporary cost pressures. Reflecting confidence in mix, scale, and pricing, Natera raised its full-year revenue outlook by more than $120 million at the midpoint and increased its full-year gross margin target to 65% at the midpoint.

Clinical Data and Publications Deepen Evidence Moat

Management highlighted a series of high-impact data readouts and publications, including bladder cancer results in a leading medical journal and results from the EXPAND trial. With 35 abstracts planned at an upcoming oncology meeting and broad evidence across tumor types, Natera is strengthening the clinical case for Signatera’s utility.

Accelerated Trial Enrollment and Elevated R&D Spend

Oncology trial enrollment and the FIND CRC study are running ahead of schedule, prompting the company to lift R&D expectations by $50 million. Natera aims to complete FIND CRC enrollment by the third quarter of 2026, positioning the program for a potential regulatory path in 2027 and pulling forward long-term growth catalysts.

Japan Emerges as a Major Signatera Opportunity

The company sees a significant commercial opportunity in Japan, where approval for Signatera is anticipated from local regulators by the second quarter of 2026. With prior use across more than 150 institutions and supportive guidelines in colorectal cancer, management believes the Japanese market could effectively double Signatera’s addressable CRC volume.

Strategic Integration and Assay Enhancements Progress

Natera reported that the integration of Foresight Diagnostics is advancing smoothly, supporting its long-term oncology roadmap. A genome-based Signatera assay incorporating phased-variant technology is expected to be available clinically later this year, with early adoption already seen in pharma and research settings.

Work-in-Process Dynamics Weigh on Q1 Margins

At quarter-end, a higher level of samples in process reduced the ratio of tests sent to those reported to about 92%, below the normal 95% to 96% range. Management estimated this dynamic created roughly a 1.5 to 2 percentage point headwind to gross margin for the quarter, partially masking underlying strength.

Timing Effects Pressure Margins Despite Stable Unit Economics

The rapid ramp in volumes also weighed on margins by roughly 2 percentage points due to timing and revenue recognition effects rather than higher per-test costs. Executives stressed that unit economics remained largely steady, suggesting these pressures should ease as operations normalize.

Temporary Cash Collection Delays Lift DSOs

A change in bundled pricing from a major government payer required repricing and system adjustments, leading to a modest step-up in days sales outstanding and temporarily delaying cash collections for Signatera. Management said these payments began flowing in April, framing the impact as a short-term working capital issue rather than a demand problem.

Acquisition-Related Costs Inflate COGS

Cost of goods sold in the quarter included a larger-than-typical stock-based compensation charge tied to the Foresight acquisition. This non-cash, acquisition-related item compressed gross margins in the period, but management characterized it as a transient drag amid otherwise improving profitability trends.

Weather Impact Damps an Otherwise Strong Quarter

Winter storms in January disrupted test volumes and led to a step-down in units that did not fully recover later in the quarter. Management suggested that absent these weather-related effects, volume and revenue growth could have been even stronger, underscoring the underlying demand trajectory.

Coverage and Pricing Uncertainty Still a Risk

Despite recent gains, coverage for Signatera remains incomplete, with additional cancer types still under review and some declines in advanced lab test status previously noted. The company acknowledged that broader Medicare and commercial coverage expansion is a work in progress and that timing remains uncertain, representing an ongoing reimbursement risk.

One-Time SG&A Items Inflate Operating Expenses

Selling, general, and administrative expenses were elevated by around $25 million of non-recurring and non-cash items in the first quarter. This temporarily lifted operating expenses as a percentage of sales, but management framed these items as non-structural and not reflective of underlying cost discipline.

Early-Stage Products Still Small but Optionality-Rich

Newer launches, such as the Zenith offering in rare disease, currently contribute minimal revenue due to low volumes. Natera views these nascent products as longer-term upside options rather than near-term growth drivers, with the core business bearing most of the financial weight today.

Payer Friction and Prior Authorization Challenges Persist

The company noted that prior authorization requirements remain a significant barrier with some payers, limiting access and slowing payments even for covered services. Management argued that any easing of these processes would represent a meaningful tailwind for both volume and cash flow as the ecosystem matures.

Guidance Raised on Strong Execution and Pricing Power

Management materially increased full-year revenue guidance, lifting the midpoint by more than $120 million, and raised its full-year gross margin outlook to 65% at the midpoint after posting just under 65% in Q1. The guidance is underpinned by robust oncology and women’s health volumes, improving ASPs with Signatera expected to exit 2026 near $1,275, and accelerated trial timelines supported by an additional $50 million in R&D investment.

Natera’s earnings call painted the picture of a company scaling rapidly, deepening its clinical moat, and translating volume growth into improved financial performance despite several short-term headwinds. For investors, the raised guidance, accelerating oncology traction, and disciplined yet aggressive R&D posture suggest a growth story that remains firmly intact, with upside tied to pricing, coverage expansion, and international adoption.